Goodwin Procter LLP advised InterVenn Biosciences on the deal. InterVenn Biosciences announced its $34 million Series B fundraising. The latest round was led by Anzu Partners…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now